Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report

Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating muscle weakness. Severe patients may develop life-threatening respiratory failure and experience crisis. Plasma exchange or intravenous immunoglobulin (IVIg) is the first-line treatment option for myasthenia crisis, but so...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in neurological disorders 2024-01, Vol.17, p.17562864241254895
Main Authors: Zhang, Zhouao, Yang, Mingjin, Luo, Tiancheng, Du, Xue, Wang, Zhouyi, Huang, Xiaoyu, Zhang, Yong
Format: Article
Language:English
Subjects:
Case Report
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating muscle weakness. Severe patients may develop life-threatening respiratory failure and experience crisis. Plasma exchange or intravenous immunoglobulin (IVIg) is the first-line treatment option for myasthenia crisis, but some patients still poorly respond to them. Here, we first reported a generalized MG patient from China who was in a state of impending myasthenic crisis and did not respond effectively to IVIg but was successfully rescued by add-on efgartigimod. Especially, we also detected meaningful changes in T-cell and B-cell subsets after efgartigimod, promoting a potential role of efgartigimod in re-establishing immune homeostasis.
ISSN:1756-2856
1756-2864
1756-2864
DOI:10.1177/17562864241254895